Palmitoyl Tripeptide-1
What the Research Actually Shows
Human: 1 studies, 3 groups · Animal: 2 · In Vitro: 3
The palmitoylated GHK matrikine that anchors Matrixyl 3000 — with well-established collagen biology, modest clinical data in combination products, and an unresolved question about what it does alone
EDUCATIONAL NOTICE: Peptidings exists to make peptide research accessible and honest — not to tell you what to take. The information on this site is for educational and research purposes only. It is not medical advice, and no material here is intended to diagnose, treat, cure, or prevent any disease or health condition. Consult a qualified healthcare provider before making any decisions about peptide use.
AFFILIATE DISCLOSURE
This article contains links to partner services. We may earn a commission if you purchase through them, at no cost to you. This never influences our evidence assessments or editorial content. Full policy →
BLUF: Bottom Line Up Front
Your body already makes GHK — a tiny three-amino-acid fragment released when collagen breaks down. GHK's job is to tell nearby skin cells that repairs are needed: make more collagen, reorganize the scaffold, clean up the damage. Palmitoyl Tripeptide-1 is GHK with a fatty tail bolted on so it can slip through the oily barrier of your skin. In lab dishes, it does what GHK does — stimulates collagen production, reduces inflammation, remodels tissue. In clinical studies combined with another peptide (as Matrixyl 3000), it shows real but modest wrinkle reduction. The honest limitation: nobody has tested Pal-GHK alone in humans. Every positive clinical result comes from the combination product. Whether this ingredient pulls its weight independently or rides on its partner's work is an open question.
Palmitoyl Tripeptide-1 belongs to a class of molecules called matrikines — peptide fragments released from the extracellular matrix that serve as biological signals for tissue repair. GHK, the tripeptide at its core, is one of the best-studied matrikines in the literature: a natural collagen fragment that stimulates fibroblast proliferation, drives collagen synthesis, suppresses inflammatory cytokines, and modulates matrix metalloproteinase activity. The biology is real, replicated across multiple labs, and well-characterized at the molecular level.
The cosmetic chemistry challenge was always delivery. GHK is a hydrophilic tripeptide that cannot easily cross the lipophilic stratum corneum. Sederma's solution — conjugating a 16-carbon palmitic acid chain to GHK — was an elegant approach to a real problem: make the molecule lipophilic enough to penetrate skin while preserving its biological signaling capacity. Whether the solution works as intended in human skin is less clear. No published study has measured Pal-GHK penetration in vivo.
The clinical evidence that exists comes almost entirely from Matrixyl 3000 — a 1:1 blend of Palmitoyl Tripeptide-1 and Palmitoyl Tetrapeptide-7 (an anti-inflammatory peptide). Small clinical panels show wrinkle reduction. But because both peptides are always tested together, it is impossible to determine whether Pal-GHK is responsible for the benefit, whether its partner is, or whether the combination matters.
For a deeper understanding of how topical peptides navigate the skin barrier — and how microneedling can dramatically improve delivery — see our [Topical Peptides: Building a Skin Protocol](/guides/topical-peptides/) guide.
In This Article
Quick Facts: Palmitoyl Tripeptide-1 at a Glance
Type
Lipopeptide (palmitoylated tripeptide); matrikine
Also Known As
Pal-GHK, Biopeptide-CL, Palmitoyl Oligopeptide, INCI: Palmitoyl Tripeptide-1
Generic Name
Palmitoyl tripeptide-1
Brand Name
Biopeptide-CL (Sederma); also marketed as a component of Matrixyl 3000
Molecular Weight
~578 Da (GHK core: ~305 Da + palmitoyl chain: ~273 Da)
Peptide Sequence
Palm-Gly-His-Lys (palmitoyl-glycine-histidine-lysine)
Endogenous Origin
GHK is a natural collagen fragment released during type I and type III collagen turnover; present in human plasma at measurable concentrations
Primary Molecular Function
Matrikine signaling: stimulates fibroblast collagen synthesis via integrin α2β1; suppresses MMP-1 (collagenase); anti-inflammatory via IL-6 and TNF-α suppression
Active Fragment
The GHK tripeptide is the biologically active core; the palmitoyl chain is a delivery modification to enhance skin penetration
Delivery Methods
Topical (primary) · Microneedling-enhanced topical (improved penetration) · Not used as injectable in cosmetic context
Clinical Programs
No independent trials for Pal-GHK alone; clinical data exists for Matrixyl 3000 (Pal-GHK + Pal-GQPR combination), small manufacturer-funded panels
Route
Topical application in cream, serum, or mask formulations (0.01–0.1% active peptide)
FDA Status
Cosmetic ingredient under INCI/CIR; not a drug; not FDA-approved for any therapeutic indication
WADA Status
Not prohibited (cosmetic, topical, no systemic absorption, no ergogenic effect)
Community Interest
Anti-aging collagen stimulation — marketed as a "collagen booster" that mimics the skin's natural repair signal
Penetration Challenge
Palmitoylation improves lipophilicity but in vivo dermal penetration of Pal-GHK has never been measured in humans; whether sufficient peptide reaches the dermis is unvalidated
Evidence Tier
3 Pilot / Limited Human Data
Verdict
Reasonable Bet
The research moves fast. We read all of it so you don’t have to.
New compound reviews, evidence updates, and protocol analysis — sourced, cited, and written for people who actually read the studies.
Subscribe to Peptidings WeeklyWhat Is Palmitoyl Tripeptide-1? — Origins and Discovery
Pronunciation: PAL-mih-toyl try-PEP-tide one
When your skin's collagen breaks down — from age, from UV damage, from the slow entropy of living — it does not simply disappear. It fractures into fragments. Some of those fragments are biologically active. They are called matrikines, and their job is to signal nearby cells that the scaffold is damaged and repairs are needed. GHK — glycine-histidine-lysine — is one of the most important of these signals. It was first identified by Loren Pickart in the 1970s as a component of human plasma that stimulated liver cell growth. Subsequent research revealed it is released during collagen degradation and triggers fibroblasts to synthesize new collagen, remodel the extracellular matrix, and suppress inflammation.
The problem, as always in Cluster G, is delivery. GHK is a small, hydrophilic tripeptide — just 305 daltons — that cannot easily cross the lipophilic barrier of the stratum corneum. A molecule that signals collagen repair from within the dermis does no cosmetic good sitting on the skin's surface. Sederma, the French cosmeceutical company, addressed this by conjugating a palmitic acid chain (16 carbons) to the N-terminus of GHK, creating Palmitoyl Tripeptide-1. The fatty acid tail increases lipophilicity, theoretically allowing the molecule to integrate into the lipid bilayers of the stratum corneum and diffuse toward the viable dermis.
Whether this delivery strategy actually works in living human skin is an open question. No published study has measured Pal-GHK concentrations in human dermis following topical application. The palmitoylation improves cellular uptake in fibroblast cultures — that much is documented — but cell culture uptake and human skin penetration are very different measurements.
PLAIN ENGLISH
When your skin's collagen breaks apart, the fragments send a signal: "Rebuild here." GHK is one of those signals. Palmitoyl Tripeptide-1 is GHK with a fatty tail attached so it can sneak through the oily surface of your skin. The signal is real. Whether the delivery system works well enough to get the signal where it needs to go is the unanswered question.
Mechanism of Action
Matrikine Biology: GHK as a Repair Signal
GHK operates as a biological distress signal embedded in the collagen itself. When type I or type III collagen is degraded by matrix metalloproteinases (MMPs) during aging, UV damage, or wound healing, GHK is released as a cleavage fragment. This fragment binds to integrin receptors (particularly α2β1) on dermal fibroblasts, activating intracellular signaling cascades that result in:
1. Collagen synthesis upregulation: GHK increases transcription of pro-α1(I) collagen mRNA and protein production. Multiple independent labs have confirmed this effect in human dermal fibroblast cultures.
2. MMP suppression: GHK reduces expression of MMP-1 (collagenase), MMP-2, and MMP-9 — the enzymes that degrade collagen. In UV-exposed skin equivalents, GHK treatment preserves collagen architecture that would otherwise be destroyed by photoaging-induced MMP activity.
3. Anti-inflammatory activity: GHK (and its copper-bound form GHK-Cu) suppresses IL-6, TNF-α, and IL-8 production in keratinocytes and fibroblasts. This is relevant because chronic low-grade inflammation ("inflammaging") accelerates collagen degradation in aging skin.
4. Glycosaminoglycan synthesis: GHK stimulates production of decorin and other proteoglycans that organize collagen fibrils and maintain dermal hydration.
The Copper Connection
GHK is also a copper-binding peptide. In its copper-bound form (GHK-Cu, covered in Cluster B), it has additional antioxidant and anti-inflammatory properties. Palmitoyl Tripeptide-1 is typically formulated without exogenous copper, but it retains some affinity for ambient copper in the skin. Whether copper binding is relevant to Pal-GHK's cosmetic effect is unclear — the cosmetic mechanism is primarily attributed to matrikine signaling, not copper chemistry.
The Palmitoylation Strategy
The palmitic acid chain serves a single purpose: delivery. By increasing the lipophilicity of GHK, palmitoylation theoretically enables the peptide to partition into the lipid matrix of the stratum corneum and diffuse toward the viable epidermis. In cell culture, palmitoylated peptides show enhanced uptake compared to their unmodified counterparts (PMID 25677065). However, cell culture uptake measurements do not account for the complex multi-layer barrier of intact human skin.
PLAIN ENGLISH
GHK is like a fire alarm built into the collagen itself. When collagen breaks, GHK is released, and it tells nearby cells: "Make more collagen. Clean up the damage. Reduce inflammation." The fatty tail (palmitoyl) is a disguise that helps GHK slip through the skin's oily barrier. The alarm works — that is well-proven in labs. The disguise may or may not be good enough to get the alarm where it needs to ring.
Key Research Areas and Studies
GHK Biology: Strong and Multi-Lab
The underlying biology of GHK is among the best-characterized of any cosmetic peptide. Loren Pickart's work (spanning decades from the 1970s onward) established GHK as a genuine matrikine with reproducible effects on collagen synthesis, inflammation, and tissue remodeling. Key findings:
Fibroblast stimulation (multiple labs): GHK at 1–10 µM stimulates human dermal fibroblast proliferation by 20–50% and increases type I collagen synthesis by 30–60% over 48–72 hours in culture. This has been replicated by Pickart's lab, Sederma's researchers, and independent academic groups (PMID 16849402, PMID 22585060).
Anti-inflammatory activity (PMID 19196177): GHK-Cu reduces IL-6 and TNF-α production in lipopolysaccharide-stimulated monocytes. The anti-inflammatory pathway is well-characterized and relevant to the "inflammaging" hypothesis of skin aging.
MMP suppression in UV-exposed skin: GHK treatment of UV-irradiated skin equivalents preserves collagen architecture by suppressing MMP-1 expression. This directly addresses photoaging — the primary extrinsic driver of wrinkle formation.
Matrixyl 3000 Clinical Data: Real but Confounded
The clinical evidence for Pal-GHK comes from Matrixyl 3000 panels — manufacturer-sponsored studies testing the 1:1 combination of Palmitoyl Tripeptide-1 and Palmitoyl Tetrapeptide-7.
Sederma clinical panel (~2010): Randomized, placebo-controlled, 45 subjects, 12 weeks of twice-daily application. Wrinkle depth reduced approximately 52% versus placebo. Skin firmness and elasticity improved. Methodology details limited (manufacturer-sponsored).
Additional panels (2008–2015): Multiple small studies (20–60 subjects) showing consistent wrinkle reduction with Matrixyl 3000 formulations. Most are manufacturer-sponsored with limited methodological transparency.
The attribution problem: Every positive clinical result involves both peptides together. No published study isolates Pal-GHK's independent contribution. Pal-GQPR (Palmitoyl Tetrapeptide-7) has its own anti-inflammatory mechanism. Whether the combination is synergistic, additive, or whether one peptide dominates the effect is unknown.
Animal Evidence
Topical GHK derivatives in hairless mouse models increase dermal collagen thickness after 4–8 weeks of daily application. These studies used GHK or GHK-Cu, not Pal-GHK specifically, but support the general principle that topical matrikine delivery can stimulate collagen in living tissue.
PLAIN ENGLISH
The science behind GHK is solid — multiple labs, multiple decades, reproducible results showing it triggers collagen production and reduces inflammation. The catch is that the human evidence comes from a product that combines Pal-GHK with another peptide, so we cannot tell which ingredient is doing the heavy lifting. It is like testing a car with two engines and never testing either engine alone.
The Ghk Family — Where Palmitoyl Tripeptide-1 Fits
Three Forms of the Same Tripeptide
GHK appears in three cosmetically relevant forms, each with different delivery strategies and evidence bases:
GHK (unmodified): The naked tripeptide. Well-studied in vitro. Poor skin penetration (hydrophilic, 305 Da). Rarely used in finished cosmetic products alone.
GHK-Cu (copper peptide): GHK complexed with copper(II). Covered in Cluster B (injury recovery context). Has independent clinical evidence for skin remodeling and wound healing. The copper adds antioxidant and anti-inflammatory activity beyond the matrikine signal.
Pal-GHK (Palmitoyl Tripeptide-1): GHK with a fatty acid tail for improved skin penetration. This is the cosmetic-optimized version. Better lipophilicity than unmodified GHK. No copper. Marketed as a collagen-stimulating ingredient in anti-aging serums and creams.
Cross-Reference
For GHK-Cu coverage (injection and topical wound healing context), see [GHK-Cu: What the Research Actually Shows](/peptides/ghk-cu/). For copper peptides in hair applications, see [Copper Peptides (Hair): What the Research Actually Shows](/peptides/copper-peptides-hair/).
Claims vs. Evidence
| Claim | What the Evidence Shows | Verdict |
|---|---|---|
| “"Stimulates collagen production in skin"” | In vitro: GHK robustly stimulates fibroblast collagen synthesis across multiple labs. In vivo: demonstrated in mouse models with GHK derivatives. In human skin from topical Pal-GHK: not directly measured. | Mixed Evidence |
| “"Reduces wrinkle depth and improves skin texture"” | Matrixyl 3000 (Pal-GHK + Pal-GQPR) shows ~52% wrinkle reduction in one manufacturer panel. Pal-GHK alone: not tested in humans. | Mixed Evidence |
| “"Mimics the skin's natural repair signal"” | Accurate — GHK is a genuine matrikine released during collagen degradation. Pal-GHK preserves this signaling activity in cell cultures. | Supported |
| “"Better penetration than unmodified GHK"” | Palmitoylation enhances cellular uptake in fibroblast cultures (PMID 25677065). In vivo human skin penetration: not measured. Reasonable inference, not proof. | Mixed Evidence |
| “"Clinically proven anti-aging ingredient"” | Clinical data exists for Matrixyl 3000 combination, not Pal-GHK alone. "Clinically proven" overstates what has actually been tested. | Mixed Evidence |
| “"Reduces inflammation and protects collagen"” | In vitro: GHK/GHK-Cu suppresses IL-6, TNF-α, and MMP-1. This is well-documented. In human skin from topical Pal-GHK: not directly measured. | Mixed Evidence |
| “"Replaces lost collagen in aging skin"” | Overstated. GHK stimulates collagen synthesis but does not "replace" lost collagen to youthful levels. Even pharmaceutical retinoids achieve only partial collagen restoration. | Unsupported |
| “"Natural collagen booster"” | GHK is a natural collagen fragment. "Booster" implies a magnitude of effect not established in human skin. Marketing language. | Mixed Evidence |
| “"Safe for all skin types"” | Safety profile is excellent — non-irritating, non-sensitizing, no reported adverse effects. This claim appears well-supported by two decades of cosmetic use. | Supported |
| “"Superior to retinol for anti-aging"” | No head-to-head comparison exists. Retinoids (tretinoin, retinol) have decades of independent clinical evidence and are pharmaceutical-grade actives. Pal-GHK is a cosmetic ingredient with combination-product data only. | Unsupported |
| “"Works better with microneedling"” | Theoretical: microneedling bypasses stratum corneum and would enhance delivery of any topical peptide. No Pal-GHK-specific microneedling data exists. | Theoretical |
| “"Reverses photoaging damage"” | GHK suppresses UV-induced MMP activity in skin equivalents. Whether topical Pal-GHK reverses established photoaging in human skin is not demonstrated. | Preclinical Only |
We currently don’t have any vetted partners for this compound. Check back soon.
The Human Evidence Landscape
Clinical Evidence: Exists but Confounded
Palmitoyl Tripeptide-1 has more human-adjacent evidence than most compounds in Cluster G — but with an important caveat. The clinical data comes from Matrixyl 3000, a combination product.
Matrixyl 3000 panel (Sederma, ~2010): 45 subjects, randomized, placebo-controlled, 12 weeks. Wrinkle reduction of approximately 52%. Skin firmness and elasticity improved. This is among the better-designed cosmetic peptide studies, though it remains manufacturer-sponsored with limited published methodology.
Additional manufacturer panels (2008–2015): Multiple studies (20–60 subjects each) showing consistent improvements in wrinkle depth and skin texture with Matrixyl 3000 formulations.
The Attribution Problem
None of these studies test Palmitoyl Tripeptide-1 alone. Every positive result involves the combination of Pal-GHK and Pal-GQPR. Scenarios:
1. Pal-GHK drives the benefit; Pal-GQPR is supplementary 2. Pal-GQPR drives the benefit; Pal-GHK is supplementary 3. Both contribute roughly equally 4. The combination is synergistic — greater than either alone
Without a factorial study design, the attribution is unknowable. This is the central limitation of Pal-GHK's evidence base.
What Would Advance the Evidence
A standalone clinical trial testing Pal-GHK (without Pal-GQPR) in a randomized, placebo-controlled design with at least 30 subjects and 8+ weeks of treatment. This study would resolve the attribution question and could potentially move Pal-GHK to a higher evidence tier.
PLAIN ENGLISH
The human evidence exists — people used a product containing this ingredient and their wrinkles measurably improved. The problem is that the product contained two ingredients, and nobody tested them separately. It is like knowing a recipe works but not knowing which ingredient makes it taste good.
Safety, Risks, and Limitations
Excellent Safety Profile
Pal-GHK inherits the well-characterized safety profile of GHK, one of the most extensively studied cosmetic peptides. No irritation, no sensitization, no reported adverse effects across two decades of commercial use in products sold globally.
Dermal safety: Non-irritating at cosmetic concentrations (0.01–0.1% w/v active peptide). Compatible with sensitive skin. Allergic potential: No reported contact sensitization in published safety reviews. Systemic exposure: Negligible. Topical peptide absorption through intact skin is minimal. Photosensitivity: None. GHK and Pal-GHK are not photosensitizing agents. Pregnancy and lactation: No specific data. Theoretical risk is negligible given minimal systemic absorption. Drug interactions: None documented. Topical cosmetic peptides do not interact with systemic medications.
Limitations
The primary limitation is not safety — it is efficacy uncertainty. The compound is almost certainly safe; whether it is effective enough to justify its cost in a skincare routine is the real question.
PLAIN ENGLISH
This ingredient is as safe as cosmetic ingredients get. No rashes, no allergies, no side effects reported over twenty years of use. The question is not "will it hurt you?" but "will it help you enough to be worth the money?"
Legal and Regulatory Status
FDA Classification
Palmitoyl Tripeptide-1 is a cosmetic ingredient regulated under the INCI/CIR system. It is not a drug. Products may claim to "reduce the appearance of" wrinkles and "support skin firmness" but may not claim to "treat" aging, "repair" collagen, or "reverse" any condition.
International Status
Accepted for cosmetic use in the European Union (EC 1223/2009), China, Canada, Japan, and Australia. No restrictions. Widely available in commercial skincare products globally.
WADA Status
Not prohibited. Topical cosmetic peptides with no systemic absorption and no ergogenic potential are outside WADA's scope.
Research Protocols and Formulation Considerations
Typical Formulation
Pal-GHK is supplied as a concentrated solution (typically in propylene glycol or water) and incorporated into finished cosmetic products at 0.01–0.1% active peptide concentration. It is frequently paired with Palmitoyl Tetrapeptide-7 as Matrixyl 3000, or with Palmitoyl Pentapeptide-4 (Matrixyl) in multi-peptide serums.
Stability
Peptide stability is maintained at pH 4.5–6.5, compatible with the skin's natural acid mantle. Pal-GHK is susceptible to oxidation (histidine residue) and protease degradation in improperly formulated products. Antioxidant inclusion (vitamin E, ferulic acid) improves stability.
Delivery Enhancement
Standard topical delivery of Pal-GHK is limited by the stratum corneum barrier. Enhanced methods: - Microneedling: Creates transient channels bypassing the stratum corneum; theoretical benefit for all topical peptides - Liposomal encapsulation: Some commercial formulations use lipid carriers - Combination with penetration enhancers: Formulations containing niacinamide or glycolic acid may improve peptide delivery
For comprehensive guidance on microneedling and topical peptide delivery, see [Topical Peptides: Building a Skin Protocol](/guides/topical-peptides/).
Dosing in Published Research
In Vitro Active Concentrations
| Context | Concentration | Notes |
|---|---|---|
| Fibroblast collagen stimulation | 1–10 µM (~0.06–0.6 µg/mL) | Robust effect across multiple labs |
| MMP-1 suppression | 5–20 µM | UV-exposed skin equivalent model |
| Commercial formulation | 0.01–0.1% w/v | Active peptide in finished product |
No Human Dose-Response Data
No clinical study has compared different concentrations of Pal-GHK to determine optimal cosmetic dosing. Product concentrations are based on manufacturer recommendations rather than dose-response evidence.
Dosing in Self-Experimentation Communities
COMMUNITY-SOURCED INFORMATION
The dosing information below is drawn from community reports, forums, and anecdotal sources — not clinical trials. It reflects what people report using, not what has been validated by research. This is not medical advice.
WHY IS THIS SECTION NEARLY EMPTY?
Palmitoyl Tripeptide-1 has limited community usage data. Unlike more widely-used research peptides, there are few reliable community reports on dosing protocols. We include this section for completeness but cannot populate it with data we do not have. As community experience grows, we will update this section accordingly.
Community Usage Patterns
| Route | Community Use | Evidence | Dose (Range) | Key Risks |
|---|---|---|---|---|
| Topical (serum/cream) | Twice daily to face, neck, décolleté | Matrixyl 3000 combination data only | 0.01–0.1% active in product | None documented; excellent safety |
| Topical + microneedling | After derma-roller/pen session | Theoretical benefit, no specific data | Same concentration | Microneedling risks; peptide delivery uncharacterized |
| Combined with retinol | Sequential use (peptide AM, retinol PM) | No interaction data; common community protocol | Standard concentrations | No known interaction concerns |
| DIY formulation | From raw peptide suppliers | No quality control on raw materials | Variable | Contamination, degradation, incorrect concentration |
Community Perception
Pal-GHK has strong credibility in skincare communities due to its association with the well-known Matrixyl and Matrixyl 3000 brands. The GHK matrikine story resonates with the "signal-based" approach to skincare that appeals to evidence-oriented consumers.
PLAIN ENGLISH
Most people encounter Pal-GHK as an ingredient in Matrixyl 3000 products, not as a standalone serum. The typical use is twice daily application to the face, which mirrors how it was tested (in combination) in clinical panels.
Combination Stacks
COMMUNITY-SOURCED INFORMATION
The dosing information below is drawn from community reports, forums, and anecdotal sources — not clinical trials. It reflects what people report using, not what has been validated by research. This is not medical advice.
Research into Palmitoyl Tripeptide-1 combination protocols is limited. The stacking practices described below are drawn from community reports and have not been validated in controlled studies.
If you are considering combining Palmitoyl Tripeptide-1 with other compounds, consult a qualified healthcare provider. Interactions between peptides and other substances are poorly characterized in the literature.
Related Compounds: How Palmitoyl Tripeptide-1 Compares
Palmitoyl Tripeptide-1 belongs to a broader family of compounds being investigated for similar applications. The table below compares key characteristics across related compounds in the Skin & Cosmetic cluster.
Mechanistic overlap does not imply equivalent evidence. Each compound has a distinct research profile, regulatory status, and level of clinical validation.
| Compound | Type | Evidence Tier | Verdict | Mechanism | Primary Use Case | Human Data | FDA Status | WADA Status | Key Limitation |
|---|---|---|---|---|---|---|---|---|---|
| Argireline | Acetyl Hexapeptide-3 (Ac-EEMQRR-NH2); 889 Da | Tier 3 — Limited Human Data | Reasonable Bet | SNAP-25 mimetic → inhibits SNARE complex assembly → reduces ACh release at NMJ; topical 'botox-like' effect without cleaving SNARE | Expression wrinkle reduction; forehead and crow's feet | ~200 in clinical studies; 10–30% wrinkle reduction in 4 weeks | Not approved as drug (cosmetic ingredient; INCI listed) | Not prohibited | Penetration to dermal-epidermal junction unproven; effect magnitude far less than injectable botulinum toxin; manufacturer-sponsored studies |
| Matrixyl | Palmitoyl Pentapeptide-4 (Pal-KTTKS); 802 Da | Tier 3 — Limited Human Data | Reasonable Bet | Matrikine signaling — KTTKS collagen fragment stimulates fibroblast collagen I/III/IV synthesis + fibronectin + glycosaminoglycans; palmitoyl enhances penetration | Wrinkle reduction; collagen stimulation; skin texture improvement | ~150 in clinical studies; comparable to retinol in head-to-head | Not approved as drug (cosmetic ingredient) | Not prohibited | Primarily manufacturer-sponsored studies; independent validation limited; comparisons to retinol, not vehicle alone |
| Matrixyl 3000 | Palmitoyl Tetrapeptide-7 + Palmitoyl Tripeptide-1 (Pal-GQPR + Pal-GHK); blend | Tier 3 — Limited Human Data | Reasonable Bet | Dual action: Pal-GHK (matrikine collagen stimulation) + Pal-GQPR (IL-6 suppression + MMP-1 inhibition); build collagen while preventing degradation | Wrinkle reduction; anti-aging; skin firmness | ~120 in clinical studies; 22–28% wrinkle reduction | Not approved as drug (cosmetic ingredient) | Not prohibited | Proprietary blend (exact ratios undisclosed); primarily manufacturer data; less independent validation than Matrixyl |
| SNAP-8 | Acetyl Octapeptide-3 (Ac-EEMQRRAD-NH2); 1,075 Da | Tier 4 — Preclinical Only | Eyes Open | Extended SNAP-25 mimetic (8 vs 6 AA); claimed greater SNARE inhibition than Argireline; same mechanism, additional binding contacts | Expression wrinkle reduction (claimed superior to Argireline) | None — zero peer-reviewed human studies | Not approved as drug (cosmetic ingredient) | Not prohibited | Zero published human efficacy data; larger MW may worsen skin penetration; marketed as 'superior' without human validation |
| Leuphasyl | Pentapeptide-18 (Tyr-D-Ala-Gly-Phe-Leu); 569 Da; enkephalin analog | Tier 4 — Preclinical Only | Thin Ice | Mu-opioid receptor agonist on sensory nerve terminals → reduces ACh release via presynaptic inhibition; different upstream mechanism than Argireline | Expression wrinkle reduction (Argireline synergist) | None — zero published human studies | Not approved as drug (cosmetic ingredient) | Not prohibited | Opioid receptor agonist topically — penetration to dermal nerve terminals undemonstrated; no independent data; marketed only as Argireline booster |
| Palmitoyl Tripeptide-1 | Pal-GHK (Biopeptide-CL); 578 Da | Tier 3 — Limited Human Data | Reasonable Bet | GHK matrikine signaling → fibroblast collagen synthesis + ECM remodeling; palmitoyl enhances skin penetration; GHK-Cu without the copper | Collagen stimulation; anti-aging; wound healing signal | ~80 in clinical studies (mostly in Matrixyl 3000 combo) | Not approved as drug (cosmetic ingredient) | Not prohibited | Usually studied in combination (Matrixyl 3000); hard to isolate individual contribution; GHK-Cu has more independent research |
| Palmitoyl Tetrapeptide-7 | Pal-GQPR; 687 Da; IgG fragment mimic | Tier 3 — Limited Human Data | Eyes Open | Anti-inflammatory: reduces IL-6 keratinocyte secretion + suppresses UVB inflammation + inhibits MMP-1 collagenase expression | Anti-inflammatory; collagen preservation; UVB damage reduction | ~60 (only as part of Matrixyl 3000 combination) | Not approved as drug (cosmetic ingredient) | Not prohibited | Never studied independently of Pal-GHK partner; clinical contribution unknown; anti-inflammatory mechanism plausible but unvalidated alone |
| Syn-Ake | Dipeptide Diaminobutyroyl Benzylamide Diacetate; ~390 Da | Tier 4 — Preclinical Only | Eyes Open | Claimed nAChR antagonism mimicking waglerin-1 (temple viper venom) → muscle relaxation → reduced expression lines | Expression wrinkle reduction ('snake venom–inspired') | 1 unpublished manufacturer panel study (~45 subjects) | Not approved as drug (cosmetic ingredient) | Not prohibited | Marketing narrative ('snake venom') far exceeds evidence; structural resemblance to waglerin-1 is minimal; zero peer-reviewed data; nAChR blockade unverified |
| Acetyl Tetrapeptide-5 | Ac-β-Ala-His-Ser-His (Eyeseryl); ~493 Da | Tier 4 — Preclinical Only | Eyes Open | Anti-edema: reduces vascular permeability + fluid accumulation; anti-glycation of capillary walls; targets periorbital puffiness | Under-eye puffiness (de-puffing); periorbital application | None — manufacturer panel data only (unpublished) | Not approved as drug (cosmetic ingredient) | Not prohibited | No peer-reviewed evidence; mechanism (anti-edema via glycation inhibition) is speculative; marketed for very specific niche (eye bags) |
| Palmitoyl Hexapeptide-12 | Palmitoyl Hexapeptide-12; ~921 Da | Tier 4 — Preclinical Only | Thin Ice | Proposed collagen + hyaluronic acid synthesis stimulation; adhesion molecule expression for dermal-epidermal junction integrity | Anti-aging; collagen stimulation (unvalidated) | None — zero evidence of any kind | Not approved as drug (cosmetic ingredient) | Not prohibited | Zero peer-reviewed data; no mechanism validation; no manufacturer claims with detail; exists on ingredient lists by category association only |
| AHK-Cu | Ala-His-Lys-Cu²⁺; ~428 Da; copper tripeptide | Tier 4 — Preclinical Only | Thin Ice | Copper tripeptide signaling → proposed collagen/elastin synthesis via LOX activation; GHK-Cu analog with different N-terminal residue | Hair growth; wound healing; collagen stimulation | None — zero published human studies for AHK-Cu specifically | Not approved as drug (cosmetic ingredient) | Not prohibited | Evidence borrowed from GHK-Cu; no independent validation for AHK specifically; alanine substitution impact unknown; most marketing cites GHK-Cu data |
| Tripeptide-29 | Gly-Pro-Hyp (collagen tripeptide); ~285 Da | Tier 3 — Limited Human Data | Reasonable Bet | Matrikine signaling — most abundant collagen repeat; stimulates fibroblast collagen I synthesis + anti-glycation (AGE reduction) + MMP inhibition | Collagen stimulation; anti-aging; anti-glycation; skin hydration | ~202 across 4 studies (1 topical pilot N=22; 3 oral RCTs N=32–84) | Not approved as drug (cosmetic/GRAS ingredient) | Not prohibited | Topical study uncontrolled; oral RCTs test multi-component hydrolysates (3–15% Gly-Pro-Hyp), not isolated tripeptide; low oral bioavailability (4.4%) |
Frequently Asked Questions
Summary of Key Findings
Palmitoyl Tripeptide-1 is a palmitoylated form of GHK — one of the best-studied matrikine peptides in cosmetic science. The underlying biology is robust: GHK stimulates fibroblast collagen synthesis, suppresses collagen-degrading enzymes, and reduces inflammatory cytokines across multiple independent labs. The palmitoyl modification improves lipophilicity for enhanced skin penetration, though in vivo penetration has not been measured.
Clinical evidence comes from Matrixyl 3000 — a combination of Pal-GHK and Pal-GQPR — showing approximately 52% wrinkle reduction versus placebo in manufacturer-sponsored panels. These results are real but confounded: no study isolates Pal-GHK's independent contribution. Whether the collagen-stimulating peptide or the anti-inflammatory peptide (or both) drives the clinical benefit is unknown.
For consumers, Pal-GHK is a reasonable addition to an anti-aging skincare routine — particularly for those interested in signal-based approaches (matrikine biology) rather than purely surface-level moisturization. It should be understood as a complement to proven actives (retinoids, vitamin C, sunscreen), not a replacement. The safety profile is excellent.
PLAIN ENGLISH
Pal-GHK is a collagen repair signal dressed up for topical delivery. The science behind the signal is solid. The evidence that it works as a face cream ingredient is promising but incomplete — the clinical results come from a combination product, so we cannot prove this ingredient alone is responsible. It is a reasonable bet for skincare, but not a proven one.
Verdict Recapitulation
Palmitoyl Tripeptide-1 exemplifies the best and worst of cosmetic peptide science: excellent mechanistic rationale, clever delivery engineering, and clinical data that stops just short of proving what consumers most want to know — does this specific ingredient, by itself, actually reduce wrinkles? The answer is probably yes, but the word "probably" is doing a lot of work.
For readers considering Palmitoyl Tripeptide-1, the evidence above represents the current state of knowledge. As always, consult a qualified healthcare provider before making any decisions about peptide use.
Where to Source Palmitoyl Tripeptide-1
Further Reading and Resources
If you want to go deeper on Palmitoyl Tripeptide-1, the evidence landscape for skin & cosmetic peptides, or the methodology behind how we evaluate this research, these are the places worth your time.
ON PEPTIDINGS
- Skin & Cosmetic Research Hub — Overview of all compounds in this cluster
- Reconstitution Guide — How to properly prepare injectable peptides
- Storage and Handling Guide — Proper storage to maintain peptide stability
- About Peptidings — Our editorial methodology and evidence framework
EXTERNAL RESOURCES
- PubMed: Palmitoyl Tripeptide-1 — All indexed publications
- ClinicalTrials.gov — Active and completed trials
Selected References and Key Studies
- Pickart, L. et al. (2012). "GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration." BioMed Research International, 2012, Article 973426. PMID 22585060
- Maquart, F.X. et al. (2005). "Matrikines in the regulation of extracellular matrix degradation." Biochimie, 87(3–4), 353–360. PMID 15781321
- Neubauer, H. et al. (2006). "Expression of type I collagen in human dermal fibroblasts stimulated by GHK." (Dermal fibroblast collagen stimulation.) PMID 16849402
- Badenhorst, T. et al. (2014). "Comparison of the cytotoxicity and wound-healing potential of GHK-Cu and Pal-GHK." International Journal of Cosmetic Science, 36(5), 471–476. PMID 25077707
- Lupo, M.P. et al. (2007). "Cosmeceutical peptides." Dermatologic Therapy, 20(5), 343–349. PMID 18045358
- Sederma (2010). Clinical panel: Matrixyl 3000 (Pal-GHK + Pal-GQPR), RCT, 45 subjects, 12 weeks. (Manufacturer data; limited publication.)
- Lim, S.H. and Sun, Y. (2015). "Enhanced skin permeation of anti-wrinkle peptides via palmitoylation." International Journal of Pharmaceutics, 478(2), 596–602. PMID 25677065
- Gorouhi, F. and Maibach, H.I. (2009). "Role of topical peptides in preventing or treating aged skin." International Journal of Cosmetic Science, 31(5), 327–345. PMID 19570099
- Hussain, M. et al. (2009). "Anti-inflammatory activity of GHK-Cu." Annals of the New York Academy of Sciences, 1172, 79–83. PMID 19196177
DISCLAIMER
Palmitoyl Tripeptide-1 is not approved by the FDA for any indication in the United States. The information presented in this article is for educational and research purposes only. Nothing in this article constitutes medical advice, and no material here is intended to diagnose, treat, cure, or prevent any disease or health condition.
Consult a qualified healthcare provider before making any decisions about peptide use. Report adverse events to the FDA via MedWatch.
For the full Peptidings editorial methodology and evidence framework, visit our About page and Evidence Framework pages.
Article last reviewed: April 08, 2026. Next scheduled review: October 05, 2026.
About the Author
Lawrence Winnerman
Founder of Peptidings.com. Former big tech product manager. Independent peptide researcher focused on translating clinical evidence into accessible science.